Artemis Investment Management LLP Sells 3,850,879 Shares of Pfizer Inc. $PFE

Key Points

• Artemis Investment Management cut its Pfizer stake by 50.6% in the third quarter, selling 3.85 million shares and retaining 3.76 million shares valued at approximately $107.3 million.
• Pfizer reported quarterly EPS of $0.77 and revenue of $15.03 billion, beating analyst expectations, while shares recently traded at $27.68. Analysts maintain a consensus “Hold” rating with an average price target of $28.61.
• Pfizer declared a quarterly dividend of $0.43 per share, equating to a 6.2% annualized yield, though its payout ratio remains elevated at 226.32%, raising concerns about long-term dividend sustainability.

Artemis Investment Management LLP lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 50.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,761,718 shares of the biopharmaceutical company's stock after selling 3,850,879 shares during the quarter. Artemis Investment Management LLP owned 0.07% of Pfizer worth $107,284,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Angeles Wealth Management LLC boosted its position in Pfizer by 2.2% during the 2nd quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company's stock worth $410,000 after acquiring an additional 358 shares during the period. Manchester Financial Inc. boosted its holdings in Pfizer by 2.9% during the second quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company's stock worth $317,000 after buying an additional 365 shares in the last quarter. Vermillion Wealth Management Inc. grew its holdings in shares of Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company's stock worth $66,000 after acquiring an additional 382 shares during the last quarter. Eagle Capital Management LLC raised its holdings in Pfizer by 0.3% during the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company's stock worth $3,554,000 after buying an additional 390 shares during the period. Finally, Delta Financial Advisors LLC lifted its position in shares of Pfizer by 1.6% in the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company's stock valued at $709,000 after acquiring an additional 398 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Shares of Pfizer stock traded down $0.32 during trading on Thursday, hitting $27.68. 12,347,028 shares of the company's stock traded hands, compared to its average volume of 40,384,527. Pfizer Inc. has a twelve month low of $23.62 and a twelve month high of $29.21. The company has a market cap of $157.80 billion, a PE ratio of 36.45, a PEG ratio of 1.85 and a beta of 0.32. The firm's fifty day moving average price is $27.56 and its 200 day moving average price is $26.48. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the prior year, the firm posted $0.78 EPS. Pfizer's quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. Pfizer's dividend payout ratio (DPR) is presently 226.32%.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Weiss Ratings upgraded Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, August 31st. Scotiabank boosted their target price on shares of Pfizer from $30.00 to $33.00 and gave the stock an "outperform" rating in a research report on Tuesday. HSBC increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a "hold" rating in a research note on Thursday, September 10th. Guggenheim dropped their price target on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a research report on Friday, August 7th. Finally, Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a research report on Sunday, September 13th. Five investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $28.61.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer’s TUKYSA regimen, in combination with trastuzumab and pertuzumab, as a front-line maintenance treatment for adults with HER2-positive metastatic breast cancer. The expanded indication could increase TUKYSA’s addressable market and support oncology revenue growth. Pfizer’s TUKYSA Regimen Receives FDA Approval
• Positive Sentiment: Pfizer reported positive Phase 3 results for LITFULO in nonsegmental vitiligo, with meaningful facial and total-body repigmentation and favorable tolerability. Planned regulatory submissions could broaden the drug’s commercial opportunity and strengthen Pfizer’s immunology pipeline. Pfizer Posted Positive Phase 3 Vitiligo Results
• Neutral Sentiment: Cantor Fitzgerald raised its Pfizer price target from $27 to $28 but kept a neutral rating, implying limited upside at recent trading levels. Cantor Fitzgerald Raises Pfizer Price Target
• Neutral Sentiment: Pfizer declared its regular $0.43 quarterly dividend, equal to $1.72 annually and a yield of roughly 6%. The payout may attract income-focused investors, although the announcement itself does not change the company’s underlying earnings outlook. Pfizer Declares Fourth-Quarter 2026 Dividend
• Negative Sentiment: Analysts and financial commentary continue to flag risks behind Pfizer’s low valuation and high dividend yield, including a previously frozen payout, elevated debt, a multibillion-dollar write-down, and a reported payout ratio above earnings. These factors raise questions about long-term dividend reliability. Pfizer’s Yield and Dividend Risks
• Negative Sentiment: Pfizer plans to cut approximately 330 jobs at its Sicily, Italy, facility, highlighting ongoing cost pressure and restructuring needs. Investors may view the reductions as evidence of continued operational challenges despite Pfizer’s cost-cutting program. Pfizer to Cut Around 330 Jobs in Italy

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company's portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.